Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
boston top stories
boulder/denver blog main
boulder/denver top stories
cancer
6
×
detroit blog main
6
×
detroit top stories
indiana blog main
indiana top stories
life sciences
national
national blog main
national top stories
6
×
new york blog main
new york top stories
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
biotech
clinical trials
fda
novartis
bristol-myers squibb
cancer immunotherapy
investing
ipo
merck
nivolumab
startups
accent therapeutics
aducanumab
What
new
6
×
bio
roundup
drug
companies
fda
ipo
life
science
activity
advantages
approval
approvals
approved
bails
bar
biogen
biogen’s
biopharmaceutical
biotechs
brand
bridgebio
brings
cancer
capital
car
clamped
club
continued
convo
covid
crop
deeper
delays
develop
developing
dna
drugs
earlier
economic
Language
unset
Current search:
new
×
cancer
×
" detroit blog main "
×
" national top stories "
×
@xconomy.com
4 years ago
Bio Roundup: Fast FDA Approvals, Biogen Delays, ORIC’s IPO & More
@xconomy.com
4 years ago
Bio Roundup: Ichnos Emerges, Beyond CAR-T, BridgeBio Bails & More
@xconomy.com
4 years ago
Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com
5 years ago
Genetic Medicine: FDA OKs 2nd Cancer Drug that Targets DNA, not Tissues
@xconomy.com
5 years ago
IPO Wave Rolls On as Five Life Science Firms Haul in $651M